Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 12/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544297 | 0.75 | ALDH1A1 (0.60) | ALDH1A1KDM4EMAOBMAPTNPC1 | |
| SCHEMBL30065841 | 0.75 | ALDH1A1 (0.60) | ALDH1A1KDM4EMAOBMAPTNPC1 | |
| SCHEMBL12478953 | 0.75 | KDM4E (0.57) | ALDH1A1KDM4EMAOBMAPTADRB2 | |
| SCHEMBL6385719 | 0.74 | ALDH1A1 (0.69) | ALDH1A1KDM4EMAOBMAPTNPC1 | |
| SCHEMBL4728857 | 0.74 | KDM4E (0.69) | ALDH1A1KDM4EMAOBMAPTNPC1 | |
| SCHEMBL2953559 | 0.74 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAOBMAPTNPC1 | |
| SCHEMBL2319848 | 0.73 | ALDH1A1 (0.67) | ALDH1A1KDM4EMAOBMAPTNPC1 | |
| SCHEMBL1569957 | 0.73 | ALDH1A1 (0.67) | ALDH1A1KDM4EMAOBMAPTNPC1 | |
| SCHEMBL1983108 | 0.73 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAOBMAPTMAOA | |
| SCHEMBL6552997 | 0.73 | ALDH1A1 (0.67) | ALDH1A1KDM4EMAOBMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759389-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759389-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759389-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7528250-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528250-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528250-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1831191-B1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-05-21 | — | — | EP | disclosed |
| EP-1831191-B1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-05-21 | — | — | EP | disclosed |
| EP-1831191-A1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831203-A1 | CHROMAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060148820-A1 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-06 | — | — | US | disclosed |
| US-20060148888-A1 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-06 | — | — | US | disclosed |
| WO-2006066756-A1 | CHROMAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066746-A1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148820-A1 | Chroman derivatives and uses thereof | RB1, RECQL, CCNY | ALDH1A1 1299/4885KDM4E 2035/4885MAOB 773/4885 |
| US-20060148888-A1 | Chroman derivatives and uses thereof | RB1, RECQL, CCNY | ALDH1A1 1299/4885KDM4E 2035/4885MAOB 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.